AKT1 and glioblastoma: Additionally, we have learned in previous studies that CHI3L1 (the homologous gene of CHI3L2) may be used as an immunomodulatory factor to affect the therapeutic efficacy of PI3K/AKT-based pathway inhibitors in glioblastoma (40).